Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LISATA THERAPEUTICS, INC.LSTA · Entity 7814 | EVP, R&D and CMO | January 09, 2026 | January 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LISATA THERAPEUTICS, INC.
Report date January 09, 2026 · Filed January 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 93,462 |
Last balance in matching sequence
After 2026-01-09 transaction · row 5
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
5 source rowsRow 1 · 2026-01-09 · Grant · Acquired 25,000 · Balance 104,794 F1: Represents 25,000 restricted stock awards granted under the Issuer's 2018 Equity Incentive Compensation Plan. The restricted stock awards vest in four equal installments, with one-fourth of the shares vesting on the date of grant and an additional one-fourth vesting on each of the first, second and third annual anniversaries of the grant date. F2: Includes 38,000 unvested restricted stock. Row 2 · 2026-01-09 · Tax withholding · Disposed 2,982 · Balance 101,812 F3: Shares withheld as payment of a tax liability on vesting of restricted stock. F2: Includes 38,000 unvested restricted stock. Row 3 · 2026-01-09 · Tax withholding · Disposed 2,982 · Balance 98,830 F3: Shares withheld as payment of a tax liability on vesting of restricted stock. F2: Includes 38,000 unvested restricted stock. Row 4 · 2026-01-09 · Tax withholding · Disposed 3,221 · Balance 95,609 F3: Shares withheld as payment of a tax liability on vesting of restricted stock. F2: Includes 38,000 unvested restricted stock. Row 5 · 2026-01-09 · Tax withholding · Disposed 2,147 · Balance 93,462 F3: Shares withheld as payment of a tax liability on vesting of restricted stock. F2: Includes 38,000 unvested restricted stock. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.97 · Expires 2036-01-09 | Direct | 13,000 |
Reported balance
After 2026-01-09 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-01-09 · Grant · Acquired 13,000 · Balance 13,000 F4: One-fourth of the shares underlying the stock options vest immediately on the grant date, with an additional one-fourth vesting on each of the first, second and third anniversaries of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents 25,000 restricted stock awards granted under the Issuer's 2018 Equity Incentive Compensation Plan. The restricted stock awards vest in four equal installments, with one-fourth of the shares vesting on the date of grant and an additional one-fourth vesting on each of the first, second and third annual anniversaries of the grant date.
F2: Includes 38,000 unvested restricted stock.
F3: Shares withheld as payment of a tax liability on vesting of restricted stock.
F4: One-fourth of the shares underlying the stock options vest immediately on the grant date, with an additional one-fourth vesting on each of the first, second and third anniversaries of the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 09, 2026 Filed Jan 13, 2026 21:07 UTC | LISATA THERAPEUTICS, INC. LSTA · Entity 7814 | GrantStock Option (Right to Buy) · Derivative | 13,000 | $0.00 Strike: $1.97 | $0.00 |
DisclosureSEC source: 0001879231-26-000003 · wk-form4_1768338428.xml · derivative · entry 6 Buck Kristen K · CIK 0001879231 · EVP, R&D and CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 13,000 shares Expires 2036-01-09 F4 · derivative.exercise_date: One-fourth of the shares underlying the stock options vest immediately on the grant date, with an additional one-fourth vesting on each of the first, second and third anniversaries of the grant date. Read SEC document |
| January 09, 2026 Filed Jan 13, 2026 21:07 UTC | LISATA THERAPEUTICS, INC. LSTA · Entity 7814 | Tax withholdingCommon Stock | 2,147 | $1.97 | $4,229.59 |
DisclosureSEC source: 0001879231-26-000003 · wk-form4_1768338428.xml · nonDerivative · entry 5 Buck Kristen K · CIK 0001879231 · EVP, R&D and CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,462 F3 · shares: Shares withheld as payment of a tax liability on vesting of restricted stock. F2 · balance_after: Includes 38,000 unvested restricted stock. Read SEC document |
| January 09, 2026 Filed Jan 13, 2026 21:07 UTC | LISATA THERAPEUTICS, INC. LSTA · Entity 7814 | Tax withholdingCommon Stock | 3,221 | $1.97 | $6,345.37 |
DisclosureSEC source: 0001879231-26-000003 · wk-form4_1768338428.xml · nonDerivative · entry 4 Buck Kristen K · CIK 0001879231 · EVP, R&D and CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,609 F3 · shares: Shares withheld as payment of a tax liability on vesting of restricted stock. F2 · balance_after: Includes 38,000 unvested restricted stock. Read SEC document |
| January 09, 2026 Filed Jan 13, 2026 21:07 UTC | LISATA THERAPEUTICS, INC. LSTA · Entity 7814 | Tax withholdingCommon Stock | 2,982 | $1.97 | $5,874.54 |
DisclosureSEC source: 0001879231-26-000003 · wk-form4_1768338428.xml · nonDerivative · entry 3 Buck Kristen K · CIK 0001879231 · EVP, R&D and CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,830 F3 · shares: Shares withheld as payment of a tax liability on vesting of restricted stock. F2 · balance_after: Includes 38,000 unvested restricted stock. Read SEC document |
| January 09, 2026 Filed Jan 13, 2026 21:07 UTC | LISATA THERAPEUTICS, INC. LSTA · Entity 7814 | Tax withholdingCommon Stock | 2,982 | $1.97 | $5,874.54 |
DisclosureSEC source: 0001879231-26-000003 · wk-form4_1768338428.xml · nonDerivative · entry 2 Buck Kristen K · CIK 0001879231 · EVP, R&D and CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,812 F3 · shares: Shares withheld as payment of a tax liability on vesting of restricted stock. F2 · balance_after: Includes 38,000 unvested restricted stock. Read SEC document |
| January 09, 2026 Filed Jan 13, 2026 21:07 UTC | LISATA THERAPEUTICS, INC. LSTA · Entity 7814 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001879231-26-000003 · wk-form4_1768338428.xml · nonDerivative · entry 1 Buck Kristen K · CIK 0001879231 · EVP, R&D and CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 104,794 F1 · shares: Represents 25,000 restricted stock awards granted under the Issuer's 2018 Equity Incentive Compensation Plan. The restricted stock awards vest in four equal installments, with one-fourth of the shares vesting on the date of grant and an additional one-fourth vesting on each of the first, second and third annual anniversaries of the grant date. F2 · balance_after: Includes 38,000 unvested restricted stock. Read SEC document |
| January 10, 2025 Filed Jan 13, 2025 21:09 UTC | LISATA THERAPEUTICS, INC. LSTA · Entity 7814 | Tax withholdingCommon Stock | 456 | $3.73 | $1,700.88 |
DisclosureSEC source: 0001879231-25-000002 · wk-form4_1736802577.xml · nonDerivative · entry 5 Buck Kristen K · CIK 0001879231 · EVP, R&D and CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,794 F3 · shares: Shares withheld as payment of a tax liability on vesting of restricted stock. F4 · balance_after: Includes 36,750 unvested restricted stock. Read SEC document |
| January 09, 2025 Filed Jan 13, 2025 21:09 UTC | LISATA THERAPEUTICS, INC. LSTA · Entity 7814 | GrantStock Option (Right to Buy) · Derivative | 13,000 | $0.00 Strike: $3.80 | $0.00 |
DisclosureSEC source: 0001879231-25-000002 · wk-form4_1736802577.xml · derivative · entry 6 Buck Kristen K · CIK 0001879231 · EVP, R&D and CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 13,000 shares Expires 2035-01-09 F5 · derivative.exercise_date: One-fourth of the shares underlying the stock options vest immediately on the grant date, with an additional one-fourth vesting on each of the first, second and third anniversaries of the grant date. Read SEC document |
| January 09, 2025 Filed Jan 13, 2025 21:09 UTC | LISATA THERAPEUTICS, INC. LSTA · Entity 7814 | Tax withholdingCommon Stock | 1,908 | $3.80 | $7,250.40 |
DisclosureSEC source: 0001879231-25-000002 · wk-form4_1736802577.xml · nonDerivative · entry 4 Buck Kristen K · CIK 0001879231 · EVP, R&D and CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,250 F3 · shares: Shares withheld as payment of a tax liability on vesting of restricted stock. F2 · balance_after: Includes 37,825 unvested restricted stock. Read SEC document |
| January 09, 2025 Filed Jan 13, 2025 21:09 UTC | LISATA THERAPEUTICS, INC. LSTA · Entity 7814 | Tax withholdingCommon Stock | 2,863 | $3.80 | $10,879.40 |
DisclosureSEC source: 0001879231-25-000002 · wk-form4_1736802577.xml · nonDerivative · entry 3 Buck Kristen K · CIK 0001879231 · EVP, R&D and CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,158 F3 · shares: Shares withheld as payment of a tax liability on vesting of restricted stock. F2 · balance_after: Includes 37,825 unvested restricted stock. Read SEC document |
| January 09, 2025 Filed Jan 13, 2025 21:09 UTC | LISATA THERAPEUTICS, INC. LSTA · Entity 7814 | Tax withholdingCommon Stock | 2,651 | $3.80 | $10,073.80 |
DisclosureSEC source: 0001879231-25-000002 · wk-form4_1736802577.xml · nonDerivative · entry 2 Buck Kristen K · CIK 0001879231 · EVP, R&D and CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,021 F3 · shares: Shares withheld as payment of a tax liability on vesting of restricted stock. F2 · balance_after: Includes 37,825 unvested restricted stock. Read SEC document |
| January 09, 2025 Filed Jan 13, 2025 21:09 UTC | LISATA THERAPEUTICS, INC. LSTA · Entity 7814 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001879231-25-000002 · wk-form4_1736802577.xml · nonDerivative · entry 1 Buck Kristen K · CIK 0001879231 · EVP, R&D and CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,672 F1 · shares: Represents 25,000 restricted stock awards granted under the Issuer's 2018 Equity Incentive Compensation Plan. The restricted stock awards vest in four equal installments, with one-fourth of the shares vesting on the date of grant and an additional one-fourth vesting on each of the first, second and third annual anniversaries of the grant date. F2 · balance_after: Includes 37,825 unvested restricted stock. Read SEC document |
| October 01, 2024 Filed Oct 2, 2024 21:21 UTC | LISATA THERAPEUTICS, INC. LSTA · Entity 7814 | Tax withholdingCommon Stock | 6,363 | $2.93 | $18,643.59 |
DisclosureSEC source: 0001879231-24-000004 · wk-form4_1727904074.xml · nonDerivative · entry 2 Buck Kristen K · CIK 0001879231 · EVP, R&D and CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,672 F3 · shares: Shares withheld as payment of a tax liability on vesting of performance-based stock units. F2 · balance_after: Includes 30,325 unvested restricted stock. Read SEC document |
| October 01, 2024 Filed Oct 2, 2024 21:21 UTC | LISATA THERAPEUTICS, INC. LSTA · Entity 7814 | GrantCommon Stock | 15,000 | $2.93 | $43,950.00 |
DisclosureSEC source: 0001879231-24-000004 · wk-form4_1727904074.xml · nonDerivative · entry 1 Buck Kristen K · CIK 0001879231 · EVP, R&D and CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,035 F1 · shares: Reflects 15,000 in performance-based stock units, the criteria for which was satisfied on October 1, 2024, and which vested in full on that same day. F2 · balance_after: Includes 30,325 unvested restricted stock. Read SEC document |
| January 10, 2024 Filed Jan 11, 2024 21:11 UTC | LISATA THERAPEUTICS, INC. LSTA · Entity 7814 | Tax withholdingCommon Stock | 512 | $3.00 | $1,536.00 |
DisclosureSEC source: 0001879231-24-000002 · wk-form4_1705007506.xml · nonDerivative · entry 4 Buck Kristen K · CIK 0001879231 · EVP, R&D and CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,035 F3 · shares: Shares withheld as payment of a tax liability on vesting of restricted stock. F4 · balance_after: Includes 30,325 unvested restricted stock. Read SEC document |
| January 09, 2024 Filed Jan 11, 2024 21:11 UTC | LISATA THERAPEUTICS, INC. LSTA · Entity 7814 | GrantStock Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $3.08 | $0.00 |
DisclosureSEC source: 0001879231-24-000002 · wk-form4_1705007506.xml · derivative · entry 5 Buck Kristen K · CIK 0001879231 · EVP, R&D and CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2034-01-09 F5 · derivative.exercise_date: One-fourth of the shares underlying the stock options vest immediately on the grant date, with an additional one-fourth vesting on each of the first, second and third anniversaries of the grant date. Read SEC document |
| January 09, 2024 Filed Jan 11, 2024 21:11 UTC | LISATA THERAPEUTICS, INC. LSTA · Entity 7814 | Tax withholdingCommon Stock | 2,147 | $3.08 | $6,612.76 |
DisclosureSEC source: 0001879231-24-000002 · wk-form4_1705007506.xml · nonDerivative · entry 3 Buck Kristen K · CIK 0001879231 · EVP, R&D and CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,547 F3 · shares: Shares withheld as payment of a tax liability on vesting of restricted stock. F2 · balance_after: Includes 31,400 unvested restricted stock. Read SEC document |
| January 09, 2024 Filed Jan 11, 2024 21:11 UTC | LISATA THERAPEUTICS, INC. LSTA · Entity 7814 | Tax withholdingCommon Stock | 3,221 | $3.08 | $9,920.68 |
DisclosureSEC source: 0001879231-24-000002 · wk-form4_1705007506.xml · nonDerivative · entry 2 Buck Kristen K · CIK 0001879231 · EVP, R&D and CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,694 F3 · shares: Shares withheld as payment of a tax liability on vesting of restricted stock. F2 · balance_after: Includes 31,400 unvested restricted stock. Read SEC document |
| January 09, 2024 Filed Jan 11, 2024 21:11 UTC | LISATA THERAPEUTICS, INC. LSTA · Entity 7814 | GrantCommon Stock | 27,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001879231-24-000002 · wk-form4_1705007506.xml · nonDerivative · entry 1 Buck Kristen K · CIK 0001879231 · EVP, R&D and CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,915 F1 · shares: Represents 27,000 restricted stock awards granted under the Issuer's 2018 Equity Incentive Compensation Plan. The restricted stock awards vest in four equal installments, with one-fourth of the shares vesting on the date of grant and an additional one-fourth vesting on each of the first, second and third annual anniversaries of the grant date. F2 · balance_after: Includes 31,400 unvested restricted stock. Read SEC document |
| September 01, 2023 Filed Sep 5, 2023 20:02 UTC | LISATA THERAPEUTICS, INC. LSTA · Entity 7814 | Tax withholdingCommon Stock | 2,908 | $2.18 | $6,339.44 |
DisclosureSEC source: 0001879231-23-000005 · wk-form4_1693944117.xml · nonDerivative · entry 1 Buck Kristen K · CIK 0001879231 · EVP, R&D and CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,915 F1 · shares: Shares withheld as payment of a tax liability on vesting of restricted stock. F2 · balance_after: Includes 15,650 unvested restricted stock awards. Read SEC document |
| January 10, 2023 Filed Jan 11, 2023 21:03 UTC | LISATA THERAPEUTICS, INC. LSTA · Entity 7814 | Tax withholdingCommon Stock | 512 | $3.20 | $1,635.84 |
DisclosureSEC source: 0001879231-23-000002 · wf-form4_167347097101144.xml · nonDerivative · entry 3 Buck Kristen K · CIK 0001879231 · EVP, R&D and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,823 F3 · shares: Shares withheld as payment of a tax liability on vesting of restricted stock. F4 · balance_after: Includes 22,733 unvested restricted stock awards. Read SEC document |
| January 09, 2023 Filed Jan 11, 2023 21:03 UTC | LISATA THERAPEUTICS, INC. LSTA · Entity 7814 | GrantStock Options (Right to Buy) · Derivative | 9,000 | $0.00 Strike: $3.00 | $0.00 |
DisclosureSEC source: 0001879231-23-000002 · wf-form4_167347097101144.xml · derivative · entry 4 Buck Kristen K · CIK 0001879231 · EVP, R&D and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2033-01-09 F5 · derivative.exercise_date: One-fourth of the shares underlying the stock options vest immediately on the grant date, with an additional one-fourth vesting on each of the first, second and third annual anniversaries of the grant date. Read SEC document |
| January 09, 2023 Filed Jan 11, 2023 21:03 UTC | LISATA THERAPEUTICS, INC. LSTA · Entity 7814 | Tax withholdingCommon Stock | 2,147 | $3.00 | $6,441.00 |
DisclosureSEC source: 0001879231-23-000002 · wf-form4_167347097101144.xml · nonDerivative · entry 2 Buck Kristen K · CIK 0001879231 · EVP, R&D and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,335 F3 · shares: Shares withheld as payment of a tax liability on vesting of restricted stock. F2 · balance_after: Includes 23,808 unvested restricted stock awards. Read SEC document |
| January 09, 2023 Filed Jan 11, 2023 21:03 UTC | LISATA THERAPEUTICS, INC. LSTA · Entity 7814 | GrantCommon Stock | 18,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001879231-23-000002 · wf-form4_167347097101144.xml · nonDerivative · entry 1 Buck Kristen K · CIK 0001879231 · EVP, R&D and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,482 F1 · shares: Represents 18,000 restricted stock awards granted under the Issuer's 2018 Equity Incentive Compensation Plan. The restricted stock awards vest in four equal installments, with one-fourth of the shares vesting on the date of grant and an additional one-fourth vesting on each of the first, second and third annual anniversaries of the grant date. F2 · balance_after: Includes 23,808 unvested restricted stock awards. Read SEC document |
| September 01, 2022 Filed Sep 2, 2022 20:05 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | Tax withholdingCommon Stock | 44,776 | $0.50 | $22,388.00 |
DisclosureSEC source: 0001879231-22-000006 · wf-form4_166214908619337.xml · nonDerivative · entry 3 Buck Kristen K · CIK 0001879231 · EVP, R&D and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 307,244 F4 · shares: Shares withheld as payment of a tax liability on vesting of restricted stock. F5 · balance_after: Includes 154,625 of unvested restricted stock. Read SEC document |
| September 01, 2022 Filed Sep 2, 2022 20:05 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | Tax withholdingCommon Stock | 25,183 | $0.50 | $12,591.50 |
DisclosureSEC source: 0001879231-22-000006 · wf-form4_166214908619337.xml · nonDerivative · entry 2 Buck Kristen K · CIK 0001879231 · EVP, R&D and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 352,020 F3 · shares: Shares withheld as payment of a tax liability on vesting of performance rights. F2 · balance_after: Includes 257,750 of unvested restricted stock. Read SEC document |
| September 01, 2022 Filed Sep 2, 2022 20:05 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | GrantCommon Stock | 58,000 | $0.50 | $29,000.00 |
DisclosureSEC source: 0001879231-22-000006 · wf-form4_166214908619337.xml · nonDerivative · entry 1 Buck Kristen K · CIK 0001879231 · EVP, R&D and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 377,203 F1 · shares: Reflects 58,000 in performance rights, the criteria for which was satisfied on September 1, 2022 and which vested on the same date. F2 · balance_after: Includes 257,750 of unvested restricted stock. Read SEC document |
| January 10, 2022 Filed Jan 12, 2022 21:18 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | GrantStock Option (Right to Buy) · Derivative | 32,500 | $0.00 Strike: $0.92 | $0.00 |
DisclosureSEC source: 0001879231-22-000002 · wf-form4_164202231648913.xml · derivative · entry 3 Buck Kristen K · CIK 0001879231 · EVP, R&D and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,500 Underlying: Common Stock · 32,500 shares Expires 2032-01-10 F4 · derivative.exercise_date: One-fourth of the shares underlying the stock options vest immediately on the grant date, with an additional one-fourth vesting on each of the first, second and third annual anniversaries of the grant date. Read SEC document |
| January 10, 2022 Filed Jan 12, 2022 21:18 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | Tax withholdingCommon Stock | 7,694 | $0.92 | $7,055.40 |
DisclosureSEC source: 0001879231-22-000002 · wf-form4_164202231648913.xml · nonDerivative · entry 2 Buck Kristen K · CIK 0001879231 · EVP, R&D and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 319,203 F3 · shares: Shares withheld as payment of a tax liability on vesting of restricted stock. F2 · balance_after: Includes 257,750 unvested restricted stock. Read SEC document |
| January 10, 2022 Filed Jan 12, 2022 21:18 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | GrantCommon Stock | 64,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001879231-22-000002 · wf-form4_164202231648913.xml · nonDerivative · entry 1 Buck Kristen K · CIK 0001879231 · EVP, R&D and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 326,897 F1 · shares: Represents 64,500 restricted stock awards granted under the Issuer's 2018 Equity Incentive Compensation Plan. The restricted stock awards vest in four equal installments, with one-fourth of the shares vesting on the date of grant and an additional one-fourth vesting on each of the first, second and third annual anniversaries of the grant date. F2 · balance_after: Includes 257,750 unvested restricted stock. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 20:04 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | GrantStock Option (Right to Buy) · Derivative | 1,137,915 | $0.00 Strike: $1.28 | $0.00 |
DisclosureSEC source: 0001879231-21-000006 · wf-form4_163069943394562.xml · derivative · entry 3 Buck Kristen K · CIK 0001879231 · EVP, R&D and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,137,915 Underlying: Common Stock · 1,137,915 shares Expires 2031-09-01 F3 · shares: One-third of the shares underlying the stock options vest immediately on the grant date, with an additional one-third vesting on each of the first and second annual anniversaries of the grant date. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 20:04 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | Tax withholdingCommon Stock | 50,103 | $1.28 | $64,131.84 |
DisclosureSEC source: 0001879231-21-000006 · wf-form4_163069943394562.xml · nonDerivative · entry 2 Buck Kristen K · CIK 0001879231 · EVP, R&D and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262,397 F2 · balance_after: Includes 209,375 unvested restricted stock awards. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 20:04 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | GrantCommon Stock | 312,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001879231-21-000006 · wf-form4_163069943394562.xml · nonDerivative · entry 1 Buck Kristen K · CIK 0001879231 · EVP, R&D and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 312,500 F1 · shares: Represents 312,500 restricted stock awards granted under the Issuer's 2018 Equity Incentive Compensation Plan. The restricted stock awards vest in three equal installments, with one-third of the shares vesting on the date of grant and an additional one-third vesting on each of the first and second annual anniversaries of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.